Evans Elizabeth, Li Libo, Min Jeong, Huang David, Urada Darren, Liu Lei, Hser Yih-Ing, Nosyk Bohdan
UCLA Integrated Substance Abuse Programs, Los Angeles, CA, USA.
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Addiction. 2015 Jun;110(6):996-1005. doi: 10.1111/add.12863. Epub 2015 Mar 15.
To estimate mortality rates among treated opioid-dependent individuals by cause and in relation to the general population, and to estimate the instantaneous effects of opioid detoxification and maintenance treatment (MMT) on the hazard of all-cause and cause-specific mortality.
Population-based treatment cohort study.
Linked mortality data on all individuals first enrolled in publicly funded pharmacological treatment for opioid dependence in California, USA from 2006 to 2010.
A total of 32 322 individuals, among whom there were 1031 deaths (3.2%) over a median follow-up of 2.6 years (interquartile range = 1.4-3.7).
The primary outcome was mortality, indicated by time to death, crude mortality rates (CMR) and standardized mortality ratios (SMR).
Individuals being treated for opioid dependence had a more than fourfold increase of mortality risk compared with the general population [SMR = 4.5, 95% confidence interval (CI) = 4.2, 4.8]. Mortality risk was higher (1) when individuals were out-of-treatment (SMR = 6.1, 95% CI = 5.7, 6.5) than in-treatment (SMR = 1.8, 95% CI = 1.6, 2.1) and (2) during detoxification (SMR = 2.4, 95% CI = 1.5, 3.8) than during MMT (SMR = 1.8, 95% CI = 1.5, 2.1), especially in the 2 weeks post-treatment entry (SMR = 5.5, 95% CI = 2.7, 9.8 versus SMR = 2.5, 95% CI = 1.7, 4.9). Detoxification and MMT both independently reduced the instantaneous hazard of all-cause and drug-related mortality. MMT preceded by detoxification was associated with lower all-cause and other cause-specific mortality than MMT alone.
In people with opiate dependence, detoxification and methadone maintenance treatment both independently reduce the instantaneous hazard of all-cause and drug-related mortality.
按病因估算接受治疗的阿片类药物依赖者的死亡率,并与普通人群进行比较,同时估算阿片类药物脱毒和维持治疗(美沙酮维持治疗)对全因死亡率和特定病因死亡率风险的即时影响。
基于人群的治疗队列研究。
将2006年至2010年在美国加利福尼亚州首次参加公共资助的阿片类药物依赖药物治疗的所有个体的死亡率数据相链接。
共有32322名个体,在中位随访2.6年期间(四分位间距=1.4 - 3.7年)有1031人死亡(3.2%)。
主要结局为死亡率,用死亡时间、粗死亡率(CMR)和标准化死亡率(SMR)表示。
与普通人群相比,接受阿片类药物依赖治疗的个体死亡风险增加了四倍多[标准化死亡率=4.5,95%置信区间(CI)=4.2,4.8]。死亡风险更高的情况为:(1)个体处于治疗中断状态时(标准化死亡率=6.1,95%置信区间=5.7,6.5)高于接受治疗时(标准化死亡率=1.8,95%置信区间=1.6,2.1);(2)脱毒期间(标准化死亡率=2.4,95%置信区间=1.5,3.8)高于美沙酮维持治疗期间(标准化死亡率=1.8,95%置信区间=1.5,2.1),尤其是在治疗开始后的2周内(标准化死亡率=5.5,95%置信区间=2.7,9.8,而标准化死亡率=2.5,95%置信区间=1.7,4.9)。脱毒和美沙酮维持治疗均能独立降低全因死亡率和药物相关死亡率的即时风险。先进行脱毒再进行美沙酮维持治疗与单独进行美沙酮维持治疗相比,全因死亡率和其他特定病因死亡率更低。
在阿片类药物依赖者中,脱毒和美沙酮维持治疗均能独立降低全因死亡率和药物相关死亡率的即时风险。